Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
1999-10-12
2001-07-03
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C424S557000
Reexamination Certificate
active
06255354
ABSTRACT:
Pulmonary surfactant is a complex of phospholipids, neutral lipids and surfactant proteins which together form a monolayered barrier between the air and the liquid surface of the lung. Pulmonary surfactant is produced in the alveolar type II cells from which it is released into the alveolar space. Pulmonary surfactant can be obtained by extraction or recombination.
To date, pulmonary surfactant has been employed for instillation in diseases or deficiencies of the lung, especially in IRDS, the respiratory distress syndrome in children, and in ARDS.
It has now been found that also for the oral treatment of diseases of the entire digestive tract (mouth, esophagus, stomach and intestine), the effectiveness and the shelf life of pulmonary surfactant can be increased by an addition of at least 0.1% by weight of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone.
2,3-Dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone is also known by the designation of coenzyme Q10. This substance plays a role in the respiratory chain and, in addition, is an antioxidant which is capable of scavenging free radicals, which are transmitted by vitamins, in particular. In addition, Q10 determines the elasticity and dynamics of cell membranes. Therefore, it has been recommended as a monopreparation and in combination with other active substances for oral administration. Further, it is offered for skin care in the form of a liposome cream which allows the active ingredient to penetrate through the horny layer barriers and then to accumulate in the various strata of the skin. However, this does not provide any indication of that even small amounts of this substance are capable of stabilizing the active substance, pulmonary surfactant, and enhancing its effectiveness. In particular, higher amounts of the active substance 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone are capable, when instilled into the lung, of strengthening the lung-resident immune system, of helping the cell to regenerate damaged cellular structures, and of simultaneously enhancing the effectiveness of pulmonary surfactant.
It is surprising thet Q10 provides dynamics not only to the lipid bilayers, but also to the pulmonary surfactant system.
REFERENCES:
patent: 4654373 (1987-03-01), Bertelli
patent: 2092969 (1996-12-01), None
Enzmann Franz
Lachmann Burkhard
Criares Theodore J.
Jacobson & Holman PLLC
Kim Jennifer
MSE Pharmazeutika GmbH
LandOfFree
Preparation of a pulmonary surfactant for instillation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation of a pulmonary surfactant for instillation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation of a pulmonary surfactant for instillation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2450537